02126.HK
JW (Cayman) Therapeutics Co. Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 1.94
−3.72%Year over year
Reported trailing growth
- Revenue
- +36.2%
- EBITDA
- +56.1%
- EBIT
- +89.2%
- EPS
- +33.8%
- Free cash flow
- +90.4%
- Operating cash flow
- +89.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +23.8%
- EBITDA
- +57.6%
- EBIT
- +47.4%
- Net income
- +8.4%
- EPS
- +9.1%
- Free cash flow
- +77.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026